Clinical Trial

Autologous huMNC2-CAR44 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)

Investigator
Complete title:
Phase I Study of Adoptive Immunotherapy for Advanced MUC1* Positive Breast Cancer with Autologous T Cells Engineered to Express a Chimeric Antigen Receptor, huMNC2-CAR44 Specific for a Cleaved Form of MUC1 (MUC1*)
Trial phase:
Phase I
Study ID:
NCT04020575
Local study ID:
RG1003846
Summary:
Phase I study of adoptive immunotherapy for advanced MUC1* positive breast cancer with autologous T cells engineered to express a chimeric antigen receptor, huMNC2-CAR44 specific for a cleaved form of MUC1 (MUC1*)
Trial keywords:
Breast Cancer
Enrollment status:
Recruiting
Trial eligibility
** For Eligibility information, please click on the "Look up trial at NIH" link above **
Other eligibility criteria may apply.
Trial exclusions
Other exclusion criteria may apply.
Learn more

Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Contact us
Seattle Cancer Care Alliance Intake Office
phone 1-800-606-7800
Toll-free